Epigendx: conduct targeted methylation assays using DNA from blood samples.
Ended Purchase Order Awarded Last action
- Contract number
- HHSN261201700080A
- Awardee
-
Epigendx Inc. UEI MTD6MD6HDC63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $35,000
Award facts
- Opportunity
-
- N02CP7268288 Solicitation number
- Conduct Targeted Methylation Assays Using DNA from Blood Samples Award Notice · Posted Aug 31, 2017
- Contract value 100% obligated
- $35,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a purchase order to Epigendx Inc. for $35,000 on September 19, 2017, to conduct targeted methylation assays using DNA from blood samples. Epigendx is a woman-owned and Asian-Pacific American-owned small business. Work is performed in Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of September 18, 2018.
Quick answers
Who was awarded contract HHSN261201700080A?
HHSN261201700080A was awarded to Epigendx Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2017.
How much is contract HHSN261201700080A worth?
The government has obligated $35,000 on HHSN261201700080A.
Was contract HHSN261201700080A competed?
The extent of competition for HHSN261201700080A was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award